Lymphocyte transformation test in pediatric drug hypersensitivity: case series report from a tertiary care hospital - Scorecard - MDSpire

Lymphocyte transformation test in pediatric drug hypersensitivity: case series report from a tertiary care hospital

  • By

  • Olga Rogozina

  • Susana Martín-López

  • Fiorela Cinthia Dueñas López

  • Zoraida del Solar Moreno

  • Larry Leiva Castrejon

  • Daniela Aguilar-Concepción

  • María Jiménez-González

  • Ana Martínez Feito

  • Miguel González-Muñoz

  • Elena Ramírez

  • May 15, 2026

  • 0 min

Share

Clinical Scorecard: Evaluation of Lymphocyte Transformation Testing for Drug Hypersensitivity in Pediatric Patients: A Case Series from a Tertiary Care Facility

At a Glance

CategoryDetail
Condition
Key MechanismsLymphocyte transformation test (LTT) evaluates T-cell mediated reactions in the context of ADR diagnosis.
Target Population
Care Setting

Key Highlights

  • sensitivity

Guideline-Based Recommendations

Diagnosis

    Management

    • Implement risk stratification for diagnostic strategies, considering patient history and severity of reactions.

    Monitoring & Follow-up

      Risks

        Patient & Prescribing Data

        LTT is valuable for evaluating T-cell mediated reactions, particularly in children without prior drug allergies.

        Clinical Best Practices

        • rationale

        Related Resources & Content

        Original Source(s)

        Lymphocyte transformation test in pediatric drug hypersensitivity: case series report from a tertiary care hospital

        • by Olga Rogozina, Susana Martín-López, Fiorela Cinthia Dueñas López, Zoraida del Solar Moreno, Larry Leiva Castrejon, Daniela Aguilar-Concepción, María Jiménez-González, Ana Martínez Feito, Miguel González-Muñoz, Elena Ramírez

        • May 15, 2026

        Related Content

        FDA Expands Afrezza to Pediatric Diabetes

        The decision was supported by the phase 3 INHALE-1 trial and additional long-term safety, efficacy, and exposure data.

        Gene Therapy Reaches XLRS Milestone

        Atsena Therapeutics reports positive interim data for XLRS gene therapy

        • May 25, 2026

        • 3 min
        Clinical Spectrum, independent risk factors, and treatment outcomes of pediatric arrhythmias: a multicenter retrospective analysis in Xinjiang